Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies Alexandra TyulyandinaDaniel HarrisonIlya Tsimafeyeu PRECLINICAL STUDIES 03 November 2016 Pages: 127 - 133
Pharmacokinetics and derivation of an anticancer dosing regimen for the novel anti-cancer agent isobutyl-deoxynyboquinone (IB-DNQ), a NQO1 bioactivatable molecule, in the domestic felid species Alycen P. LundbergJoshua M. FrancisTimothy M. Fan PRECLINICAL STUDIES 14 December 2016 Pages: 134 - 144
Sunitinib-paracetamol sex-divergent pharmacokinetics and tissue distribution drug-drug interaction in mice Ming Hui LiewSalby NgIgnacio Segarra PRECLINICAL STUDIES 09 January 2017 Pages: 145 - 157
Targeting specificity protein 1 transcription factor and survivin using tolfenamic acid for inhibiting Ewing sarcoma cell growth Sagar ShelakeUmesh T. SankpalRiyaz Basha PRECLINICAL STUDIES 26 December 2016 Pages: 158 - 165
Zebrafish phenotypic screen identifies novel Notch antagonists Vithya VelaithanKazuhide Shaun OkudaVyomesh Patel PRECLINICAL STUDIES 05 January 2017 Pages: 166 - 179
Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors Muhammad S. BegAndrew J. BrennerDavid S. Hong PHASE I STUDIES 05 December 2016 Pages: 180 - 188
A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone James M. ClearyLee S. RosenWeijing Sun PHASE I STUDIES Open access 23 January 2017 Pages: 189 - 197
Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors Luis Paz-AresMartin ForsterEmiliano Calvo PHASE I STUDIES 21 November 2016 Pages: 198 - 206
Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors Noboru YamamotoHiroshi NokiharaTomohide Tamura PHASE I STUDIES Open access 08 December 2016 Pages: 207 - 216
Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy Yuichi TamboYukio HosomiTomohide Tamura PHASE II STUDIES 30 January 2017 Pages: 217 - 226
A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016) Satoru MiuraMakoto MaemondoHirohisa Yoshizawa PHASE II STUDIES 01 February 2017 Pages: 227 - 234
Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C Khaldoun AlmhannaMaria Luisa Limon MironThea Kalebic PHASE II STUDIES 11 February 2017 Pages: 235 - 241
Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old Frederic BigotPascaline Boudou-RouquetteFrancois Goldwasser SHORT REPORT 29 October 2016 Pages: 242 - 246
Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors Pierre LoulergueMansouria MeradOlivier Mir SHORT REPORT 12 November 2016 Pages: 247 - 249
Erratum to: Zebrafish phenotypic screen identifies novel Notch antagonists Vithya VelaithanKazuhide Shaun OkudaVyomesh Patel Erratum 10 February 2017 Pages: 250 - 250